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A B S T R A C T
Background/aim: Deﬁciency of acetyl-L-carnitine (ALC) and L-carnitine (LC) appears to play a role in
peripheral diabetic neuropathy, although the evidence in humans is still limited. We conducted a
systematic review and meta-analysis investigating the effect of ALC on pain and electromyographic
parameters in people with diabetic neuropathy.
Methods: A literature search in major databases, without language restriction, was undertaken. Eligible
studies were randomized controlled trials (RCTs) or pre- and post-test studies. The effect of ALC
supplementation on pain perception and electromyographic parameters in patients with diabetic
neuropathy was compared vs. a control group (RCTs). The effect of ALC/LC on electromyographic
parameters were also calculated vs. baseline values. Standardized mean differences (SMD) and 95%
conﬁdence intervals (CIs) were used for summarizing outcomes.
Results: Six articles, with a total of 711 diabetic participants, were included. Three RCTs (340 treated with
ALC vs. 203 placebo and 115 with methylcobalamine) showed that ALC reduces pain perception
(SMD = 0.45; 95% CI: 0.86 to 0.04; P = 0.03; I2 = 85%). Compared to controls, ALC supplementation
improved nerve conduction velocity and amplitude response for ulnar nerve (both sensory and motor
component). Compared to baseline values, ALC/LC supplementation improved nerve conduction velocity
for all the sensory and motor nerves (except ulnar and peroneal) investigated and the amplitude of all
nerves. The onset of adverse events was generally limited to minor side effects.
Conclusion: ALC appears to be effective in reducing pain due to diabetic neuropathy compared to active or
placebo controls and improving electromyographic parameters in these patients.
C 2017 Elsevier Masson SAS and European Union Geriatric Medicine Society. All rights reserved.
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Peripheral neuropathy is one of the most prevalent complica-
tions of diabetes mellitus, with prevalence estimates ranging from* Corresponding author. Tel.: +00390498218492; fax: +00390498211218.
E-mail address: ilmannato@gmail.com (N. Veronese).
http://dx.doi.org/10.1016/j.eurger.2017.01.002
1878-7649/C 2017 Elsevier Masson SAS and European Union Geriatric Medicine Societ12 to 50% [1]. The most common form of peripheral neuropathy in
diabetes is the distal symmetric polyneuropathy, a form affecting
both sensory and motor nerves [1].
The complications due to diabetic neuropathy are multiple (e.g.
asthenia, paresthesia in initial stages and in advanced ones ulcers
and deformation of lower extremities) and often associated with
higher presence of disability and poor quality of life [2]. Thesey. All rights reserved.
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common symptoms associated with diabetic neuropathy [1].
The management of symptomatic diabetic sensory neuropathy
presents a therapeutic challenge for the physicians, since the
therapies for this conditions are predominantly limited to seeking
to obtain good glucose control and the use of analgesic medications
[3,4]. Such interventions are often not effective in symptoms and
do not address the pathogenesis of diabetic neuropathy. Although
the pathogenesis of this condition is not completely understood,
one of the main mechanisms responsible seems to be the reduced
availability of acetyl groups, necessary for the synthesis of choline
[5]. A deﬁciency of acetyl-L-carnitine (ALC) and L-carnitine (LC)
seems to play a pivotal role in this pathway [6], since a deﬁcit of
ALC has been shown to cause damage to the myelin sheath [7]. In
animal models, the exogenous administration of ALC increases
artemin levels and enhances the expression of nerve growth factor
(NGF) [8,9], enhances antioxidant activity [10] and microvascular
protein permeability [11], and induces long-term upregulation of
the presynaptic mGlu2 receptors [12]; in this way, ALC supple-
mentation induces neuroprotective, neurotrophic and analgesic
effects in the peripheral nervous system [12,13].
Regarding human beings, ALC is recommended in the tier 1 of
neuropathic pain treatments by the Mayo Clinic proceedings [14],
and a recent meta-analysis has conﬁrmed that administration of
ALC was able to improve pain perception in people affected by
peripheral neuropathy [15]. Although this work advanced our
knowledge regarding this important topic, a number of limitations
persist, for instance, the authors considered all kinds of neuropa-
thies together (although they have different pathogeneses) and
they did not investigate the effect of ALC on electromyographic
parameters, the most common method for diagnosis and evaluat-
ing peripheral neuropathy [1].
Given the mentioned limitations in the literature, we aimed to
investigate the effect of ALC on pain and electromyographic
parameters in diabetic neuropathy. We hypothesized that ALC
supplementation is beneﬁcial for symptomatology and electro-
myographic features of diabetic neuropathy.
2. Methods
This systematic review adhered to the Prisma [16] and Moose
[17] statements and followed a structured, but unpublished
protocol.
2.1. Data sources and literature search strategy
Two investigators (NV and GS) independently conducted a
literature search using PubMed, Embase, Scopus, Cochrane central
register of controlled trials and Clinicaltrials.gov without language
restriction, from database inception until 5th June 2016 for
randomized controlled trials (RCTs) and descriptive studies (i.e.
without a control group) investigating the effect of ALC supple-
mentation in patients with diabetic neuropathy.
In PubMed, the following search strategy was used: ‘‘(carnitine
[Text word] OR ‘‘Carnitine’’[Mesh]) AND (diabet*) AND (neurop*)’’.
Conference abstracts and reference lists of included articles were
hand-searched to identify and potential additional relevant
articles. Any inconsistencies were resolved by consensus with a
third author (SM).
2.2. Study selection
Inclusion criteria for this meta-analysis were:
 RCTs or pre- or post-test studies;
 included diabetic participants with peripheral neuropathy
diagnosed through electromyography (EMG); investigated the use of carnitine supplementation (regardless of
administration route);
 included data regarding pain (due to neuropathy) and/or
regarding EMG parameters.
Studies were excluded if:
 did not include humans;
 investigated the effect of carnitine on other causes of
neuropathic pain (e.g. due to chemotherapy);
 included participants with diabetes, but without a neuropathy.
2.3. Data extraction
Two independent investigators (NV and BS) extracted key data
from the included articles in a standardized Excel sheet. A third
independent investigator (GS) checked the extracted data.
For each article, we extracted data about authors, year of
publication, country, study design (RCT/descriptive), medications
used for the treatment of diabetes, daily ALC/LC dosage, follow-up
duration (in weeks) and mean age (by treatment type: ALC or
control group). Finally, we extracted data regarding the adverse
events reported in each study.
2.4. Outcomes
The primary outcome was the change of pain perception at
follow-up assessed through a validated scale (e.g. Visual Analogue
Scale) between participants treated with ALC vs. controls.
As secondary outcomes, we considered EMG parameters in
terms of conduction velocity and response amplitude in terms of:
 differences between follow-up and baseline (pre and post
treatment) in ALC vs. controls;
 within patients treated comparing the data at follow-up vs.
baseline in people treated with ALC/LC.
2.5. Assessment of study quality
Two authors (NV, GS) completed scoring using the Jadad’s scale
[18] for assessing the quality and the risk of bias of the RCTs
included. This quantiﬁes the trial quality based on the description
and appropriateness of randomization (2 points), blinding
procedures (2 points), and description of withdrawals (1 point).
A value less than 3 (over a maximum of 5) usually indicates a low-
quality study at high risk of bias [19].
2.6. Data synthesis and statistical analysis
All analyses were performed using comprehensive meta-
analysis (CMA) 3 and Revman 5.3. Outcomes with at least two
studies were meta-analyzed, and in case of only one study, we
described the data in a descriptive summary. When multiple
assessments were made, the longest follow-up time was included
in our analyses.
The primary analysis compared the values of pain scales
between participants treated with ALC supplementation vs.
controls. We calculated the difference between the means of the
treatment and placebo groups using the follow-up data through
standardized mean differences (SMD) with their 95% conﬁdence
intervals (CIs), applying a random-effect model [20].
For the secondary analysis, a similar analysis was made for ALC,
whilst for ALC/LC this analysis for EMG parameters was limited to
the differences between follow-up and baseline values (pre- and
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quantitative data on EMG were used.
Heterogeneity across studies was assessed by the I2 metric and
Chi2 statistics. Given signiﬁcant heterogeneity (I2  50%, P < 0.05)
and for outcomes having at least 5 studies, we planned to run a
meta-regression analysis. No sufﬁcient number of studies was
reached by any outcome included.
Publication bias was assessed by a visual inspection of funnel
plots and calculating the Egger bias test [21]. Then, to account for
publication bias, we used the trim-and-ﬁll method, based on the
assumption that the effect sizes of all the studies are normally
distributed around the center of a funnel plot; in the event of
asymmetries, the test adjusts for the potential effect of unpub-
lished studies [21]. For all analyses, a P-value less than 0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Search results
Altogether, the searches yielded 230 non-duplicated articles.
After excluding 218 articles based on title/abstract review
(predominantly because they did not include participants with
diabetic neuropathy), 12 articles were retrieved for full text review.
Finally, six articles [22–27] were included in the qualitativeRecords  iden tified  throu gh database 
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Fig. 1. Prisma ﬂsynthesis and ﬁve [23–27] were included in the quantitative
analysis. Of the included articles, three were RCTs [23–25] (Fig. 1).
3.2. Study and patient characteristics
Full descriptive details of the included studies are reported
in Supplementary Table 1 (ALC-RCTs) and Supplementary
Table 2 (LC-descriptive studies). All the studies together
included a total of 711 diabetic participants with peripheral
neuropathy.
The three RCTs [23–25] included in our meta-analysis included
a total of 658 diabetic participants with neuropathy. Across the
3 RCTs, 340 were treated with ALC (mean age = 57.8 years), whilst
the 318 controls (mean age = 57.8 years) were treated with placebo
(n = 203) or methylcobalamine (n = 115), as reported in the
Supplementary Table 1. All the three studies included both
type 1 and 2 diabetes with a concomitant treatment with oral
antidiabetic agents and insulin. The median follow-up period was
48 weeks (range: 24–52). The quality, assessed through the Jadad’s
scale [18], indicates a low risk of bias.
The other three descriptive studies [22,26,27] reporting data
regarding the effect of LC on diabetic neuropathy are described in
the Supplementary Table 2. All three descriptive studies were
conducted in Turkey and involved 53 people with type 1 and/or
2 diabetes. The median follow-up period for these studies was
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Fig. 2. Effect of acetyl-L-carnitine (ALC) on neuropathic pain in randomized controlled trials. CI: conﬁdence intervals; IV: inverse variance; SD: standard deviations.
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Fig. 2 shows the effect of ALC on pain in people with diabetic
neuropathy. Two studies [23,25] reported the pain perception
using a visual analogue scale, whilst another RCT [24] used the
neuropathy symptom score. Overall, ALC signiﬁcantly reduced
pain perception in 340 participants vs. 318 controls (203 treated
with placebo and 115 with methylcobalamine) (4 cohorts in 3 RCTs
[23–25]; SMD = 0.45; 95% CI: 0.86 to 0.04; P = 0.03; I2 = 85%).
Although the data were heterogeneous, a meta-regression
analysis was not possible due to the limited number of the studies
available, whilst the evidence of the publication bias was low
(Egger bias test = 0.78; P = 0.48).
3.4. Meta-analysis of the effect of ALC and ALC/LC on
electromyographic parameters
All studies (except one [22]) reported the effect of ALC/LC on
EMG parameters. We were able to meta-analyze pre- and post-test
changes from 4 of the 5 studies reporting data on EMG parameters.
One study [25] reported the data only as descriptive ﬁndings.
Table 1 shows the meta-analysis of EMG parameters between
patients treated with ALC vs. controls in two studies [23,24]. Com-
pared to controls, the treatment with ALC improved the nerve
conduction velocity a both sensory (SMD = 0.60; 95% CI: 0.35–0.86,
P < 0.0001; I2 = 94%) and motor (SMD = 0.67; 95% CI: 0.43–0.91,
P < 0.0001; I2 = 0%) ulnar nerve. We observed a similar improve-
ment for both sensory and motor component for ulnar nerve,
taking response amplitude as outcome. ALC improved also the
response amplitude for motor nerve median as reported in Table
1. Except few exceptions, the heterogeneity was high. The
publication bias analysis was not feasible due to the limited
number of studies available for each outcome.
Table 2 shows the meta-analysis of EMG parameters
calculated as the difference between follow-up and baseline
values after ALC/LC treatment. Regarding nerve conductionTable 1
Electromyographic ﬁndings of the studies investigating the role of acetyl-L-carnitine (A
Analysis Meta-analysis 
SMD 95% CI 
Nerve conduction velocity
SN median (m/s) 0.26 0.58 
SN ulnar (m/s) 0.60 0.35 
SN sural (m/s) 0.56 0.09 
MN median (m/s) 0.45 0.20 
MN ulnar (m/s) 0.67 0.43 
MN peroneal (m/s) 0.83 0.20 
Response amplitude
SN median (uV) 0.67 0.89 
SN ulnar (uV) 0.99 0.72 
SN sural (uV) 0.71 0.66 
MN median (mV) 0.89 0.42 
MN ulnar (mV) 0.74 0.46 
MN peroneal (mV) 0.49 0.57 
CI: conﬁdence intervals; MN: motor nerve; SMD: standardized mean difference; SN: sen
extracted from two studies [21,22].velocity, ALC/LC signiﬁcantly improved all the three sensory
nerves investigated with a SMD ranging from 0.76 (95% CI: 0.50–
1.02; 3 studies; 122 participants) for median nerve to 1.01 m/s
(95% CI: 0.74–1.29; 3 studies; 118 participants) for sural nerve.
A similar ﬁnding was evident for median (SMD = 0.54 m/s;
95% CI: 0.25–0.83; 4 studies; 124 participants) and tibial motor
nerve (SMD = 0.49 m/s; 95% CI: 0.18–0.79; 3 studies; 86 parti-
cipants) (Table 2, upper part).
For all these results, the heterogeneity was low (as shown by
the I2 < 50%) and publication bias was unlikely, except for ulnar
motor nerve for which, however, the trim and ﬁll procedure did not
change our results.
The effect of ALC/LC on response amplitude seems to be
comparable to the effect of nerve conduction velocity. ALC/LC were
able to improve the response amplitude for all sensory nerves
(with a SMD ranging from 0.79 for sural to 1.04 uV for median
nerve) and for all motor nerves (SMD from 0.60 for peroneal to
0.74 mV for tibial), except for median nerve. However, after
trimming one study at the left of the mean, also this ﬁnding
becomes statistically signiﬁcant (SMD = 1.46 mV; 95% CI: 0.24–
2.69) (Table 2, lower part).
Contrary to the ﬁndings observed for conduction velocity, the
heterogeneity for response amplitude was generally high
(I2 > 70%) for all the outcomes included.
Finally, Sima et al., in their trial [25], reported a not signiﬁcant
effect of ALC on EMG parameters, when compared to placebo, but
the data after/before ALC supplementation were not available.
Anyway, the trial [25] showed signiﬁcant improvements in sural
nerve ﬁber numbers and regenerating nerve ﬁber clusters, and
vibration perception was improved.
3.5. Meta-regression analysis
Although some outcomes suffered of high heterogeneity (as
indicated by an I2  50%), the number of the studies for each
outcome was too low for doing a reliable meta-regression analysis.LC) compared to controls.
Heterogeneity
P-value I2
1.09 0.55 80
0.86 < 0.0001 94
1.21 0.09 75
1.10 0.18 63
0.91 < 0.0001 0
1.85 0.11 94
2.23 0.40 93
1.26 < 0.0001 93
2.07 0.31 93
1.36 < 0.0001 0
1.03 < 0.0001 0
1.54 0.37 85
sory nerve. Bold values indicate signiﬁcant results (P-values < 0.05). All the data are
Table 2
Electromyographic ﬁndings of the studies investigating the role of acetyl-L-carnitine and L-carnitine compared to baseline.
Analysis Number of
studies
(references)
Number
participants
Meta-analysis Heterogeneity Publication bias Classic fail
safe (n)
SMD 95% CI P-value I2 Egger bias
and P-value
Trim and ﬁll (95% CI)
[trimmed]
Nerve conduction velocity
SN median (m/s) 3 [21,22,24] 122 0.76 0.50 1.02 < 0.0001 0 1.90; 0.12 0.66 (0.44–0.89) [2] 24
SN ulnar (m/s) 3 [21,22,24] 119 0.89 0.53 1.26 < 0.0001 44 3.22; 0.79 Unchanged 31
SN sural (m/s) 3 [21,22,24] 118 1.01 0.74 1.29 < 0.0001 0 3.10; 0.72 Unchanged 38
MN median (m/s) 4 [21,22,24,25] 124 0.54 0.25 0.83 < 0.0001 18 1.58; 0.55 0.45 (0.17–0.73) [1] 12
MN ulnar (m/s) 4 [21,22,24,25] 189 0.48 0.11 1.07 0.10 85 7.80; 0.03 Unchanged 25
MN tibial (m/s) 3[22,24,25] 86 0.49 0.18 0.79 0.002 0 1.70; 0.05 0.42 (0.17–0.66) [2] 5
MN peroneal (m/s) 4 [21,22,24,25] 192 0.62 0.27 1.50 0.17 94 9.81; 0.29 Unchanged 42
Response amplitude
SN median (uV) 3 [21,22,24] 102 1.04 0.12 1.95 0.03 86 2.37; 0.76 Unchanged 32
SN ulnar (uV) 3 [21,22,24] 149 0.85 0.04 1.65 0.04 89 7.98; 0.33 Unchanged 40
SN sural (uV) 4 [21,22,24,25] 129 0.79 0.19 1.40 0.01 81 11.8; 0.11 Unchanged 37
MN median (mV) 4 [21,22,24,25] 90 1.09 0.16 2.33 0.09 93 5.01; 0.72 1.46 (0.24–2.69) [1] 36
MN ulnar (mV) 4 [21,22,24,25] 156 0.72 0.26 1.19 0.002 71 5.12; 0.14 Unchanged 36
MN tibial (mV) 3 [22,24,25] 91 0.74 0.11 1.34 0.02 74 8.59; 0.23 Unchanged 16
MN peroneal (mV) 4 [21,22,24,25] 125 0.60 0.04 1.16 0.04 76 1.50; 0.76 Unchanged 15
CI: conﬁdence intervals; MN: motor nerve; SMD: standardized mean difference; SN: sensory nerve. Bold values indicate signiﬁcant results (P-values < 0.05).
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As showed in the Supplementary Table 3, no severe side effects
(e.g. death, onset of cardiovascular diseases) emerged after
treatment with ALC/LC in RCTs and in one study [25], some
neurological signs (pain, hyperesthesia and paraesthesia) were
more frequent in placebo group than ALC. All the studies, however,
reported that people treated with ALC/LC experienced some
gastrointestinal side effects of minor entity, like vomiting or
nausea.
4. Discussion
In this systematic review and meta-analysis including for pain,
three RCTs and three observational studies and for EMG two
studies for a total of 711 diabetic participants, we showed that ALC
could have a beneﬁcial effect on pain and electromyographic
parameters in diabetic people with peripheral neuropathy
compared to controls, whilst the treatment with ALC/LC was able
to improve EMG parameters compared to baseline.
Compared to the control group, ALC was associated with a
signiﬁcant reduction in pain perception in people affected by
diabetic neuropathy. The mechanism leading to this analgesic
effect seems to be related to the acetylation and the activation of
the transcription of NF-kB, promoted by ALC, acting as a donor of
acetyl groups [12,28]. This activation corresponds to an increase in
the expression of mGlu-2 receptor that link glutamate in the
synapses of the dorsal horn with a consequent reduction in pain
hypersensitivity [12,28]. As previously reported in the meta-
analysis of Li et al. [15], the effect of ALC on neuropathic pain was
stronger in diabetes than other conditions. One hypothesis is that
in diabetes, the effect of glutamate is more pronounced than other
neuropathies [29,30] and consequently, ALC works better in this
condition.
The descriptive studies reported that LC is able to improve EMG
parameters, conﬁrming that, beyond the activity of ALC as a donor
of acetyl groups, carnitine supplementation anyway presents a
neurotrophic effect. The reasons of why some nerves have and
other have not a beneﬁcial effect from LC is not known and further
research is needed to disentangle this issue.
In our meta-analysis, ALC/LC were also able to signiﬁcantly
improve the nerve conduction velocity and the amplitude of
several upper and lower limbs nerves. In EMG, latency is the time
needed for the stimulus to initiate an evoked potential: thisparameter reﬂects the conduction along the fastest ﬁbers. Peak
latency is the latency along the majority of axons and is measured
at the peak amplitude. Both these parameters are affected by the
state of the myelination of the nerve [31] Reduction of amplitudes
of recorded responses generally indicates a loss of axons [31]. The
conduction velocity also depends on the state of myelination and is
often decreased in disorders affecting nerve myelination, although
it could be normal if a few myelinated axons remain intact
[31]. From a molecular point of view, ALC seems to able to enhance
the expression of NGF and its receptors, increases the regeneration
of the nerve reducing the myelinic degeneration and ﬁnally
improves the anatomy and physiology of the nerve [8,14,32]. All
these factors probably contributed to the effect of ALC on EMG
parameters.
The beneﬁts of ALC treatment in diabetic patient are ampliﬁed by
the fact there are to date very few adverse events reported in the
literature. All the three RCTs [23–25], in fact, reported a similar
frequency of side effects among people treated with ALC and
controls, whilst the only descriptive study [26] reporting adverse
events showed that only 2 patients were affected by an adverse effect
and they did not discontinue the treatment with this supplement.
The ﬁndings of our work should be interpreted within its
limitations. First, the ﬁndings of EMG between treated and control
group were substantially limited only to two studies. Thus, we
were not able to run a reliable meta-regression analysis to verify if
the improvement in the EMG parameters was associated with
decrease in pain. Other trials are needed to disentangle this issue.
Second, most of all the amplitude parameters and the primary
outcome suffered from high heterogeneity, and we were not able
the address this heterogeneity. Finally, the length of follow-up of
all the studies included was relatively short and future studies with
a longer follow-up period are needed. Similarly, the mean dosage
of ALC/LC was highly variable among the studies. Among the
strengths of our work, we can consider that is the ﬁrst meta-
analysis investigating the effect of ALC on pain and EMG
parameters on diabetic neuropathy. Moreover, our review suggests
that ALC treatment is well-tolerated in diabetic patients.
In conclusion, our work suggests that ALC may be effective in
reducing pain due to diabetic neuropathy compared to active or
placebo controls. Moreover, ALC seems to improve some EMG
parameters for both sensory and motor nerves compared to
controls and similarly to LC compared to baseline estimates. Future
RCTs are needed conﬁrm our ﬁndings, particularly regarding the
EMG parameters compared to placebo.
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